{"id":58863,"date":"2026-03-05T15:53:39","date_gmt":"2026-03-05T07:53:39","guid":{"rendered":"https:\/\/flcube.com\/?p=58863"},"modified":"2026-03-05T15:53:40","modified_gmt":"2026-03-05T07:53:40","slug":"abb-bio-tech-wins-fda-ind-approval-for-mrna-mpox-vaccine-chinas-first-u-s-cleared-candidate-targets-immunocompromised-populations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58863","title":{"rendered":"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#8217;s First U.S.-Cleared Candidate Targets Immunocompromised Populations"},"content":{"rendered":"\n<p><strong>Ab&amp;B Bio-Tech CO., LTD. JS<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2627:HKG\">HKG: 2627<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved the <strong>Investigational New Drug (IND)<\/strong> application for its <strong>self-developed mRNA Mpox vaccine<\/strong>. The candidate becomes <strong>China&#8217;s first<\/strong> and the <strong>world&#8217;s third<\/strong> mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance (Phase I-ready)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Investigational mRNA Mpox vaccine<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Ab&amp;B Bio-Tech CO., LTD. JS (HKG: 2627)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>China&#8217;s 1st; World&#8217;s 3rd mRNA Mpox vaccine with FDA IND<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>4\u202fMar\u202f2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Phase I clinical trial initiation in U.S.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>mRNA Candidate<\/th><th>Comparator (Tiantan Strain)<\/th><th>Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Mpox Neutralizing Antibodies<\/strong><\/td><td>Significantly higher levels<\/td><td>Live-attenuated vaccinia virus<\/td><td>Superior immunogenicity<\/td><\/tr><tr><td><strong>Cross-Reactivity<\/strong><\/td><td>Broad-spectrum against multiple orthopoxvirus antigens<\/td><td>Limited<\/td><td>Enhanced protection spectrum<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Replication-deficient mRNA platform<\/td><td>Replication-competent live virus<\/td><td>Suitable for immunocompromised<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> mRNA-encoded orthopoxvirus antigens eliciting humoral and cellular immunity<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Non-replicating platform eliminates risk of systemic vaccinia infection in immunodeficient hosts<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-positioning-amp-market-opportunity\">Competitive Positioning &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Population<\/strong><\/td><td>HIV-positive individuals and other immunocompromised patients contraindicated for live vaccines<\/td><\/tr><tr><td><strong>Global Supply Gap<\/strong><\/td><td>Current licensed Mpox vaccines (JYNNEOS, ACAM2000) have immunogenicity limitations in HIV populations<\/td><\/tr><tr><td><strong>Market Entry<\/strong><\/td><td>Potential first-mover advantage in mRNA Mpox segment for high-risk demographics<\/td><\/tr><tr><td><strong>Manufacturing<\/strong><\/td><td>mRNA platform enables rapid scale-up and variant-adaptable formulation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development:<\/strong> Phase I trial design expected to include HIV-positive cohorts to demonstrate safety\/immunogenicity in target population<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Parallel China NMPA filing anticipated; potential for FDA Breakthrough Therapy designation given unmet need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation Impact:<\/strong> IND approval validates Ab&amp;B&#8217;s mRNA platform technology; shares (HKG: 2627) expected to react positively<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Multinational vaccine manufacturers may seek co-development\/commercialization rights for ex-China markets<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Platform applicability to other orthopoxviruses (smallpox, cowpox) and hemorrhagic fever viruses<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for Ab&amp;B Bio-Tech&#8217;s mRNA Mpox vaccine. Actual results may differ due to trial outcomes, manufacturing capabilities, and competitive dynamics in the infectious disease vaccine market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030400621_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030400621_c.\"><\/object><a id=\"wp-block-file--media-4d7eaf3e-8db8-4b7b-b70c-a8eb03b84b34\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030400621_c.pdf\">2026030400621_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030400621_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4d7eaf3e-8db8-4b7b-b70c-a8eb03b84b34\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ab&amp;B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4291,62,4334,63,12],"class_list":["post-58863","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abb-bio-tech","tag-clinical-trial-approval-initiation","tag-hkg-2627","tag-mrna","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#039;s First U.S.-Cleared Candidate Targets Immunocompromised Populations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ab&amp;B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China&#039;s first and the world&#039;s third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58863\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#039;s First U.S.-Cleared Candidate Targets Immunocompromised Populations\" \/>\n<meta property=\"og:description\" content=\"Ab&amp;B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China&#039;s first and the world&#039;s third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58863\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T07:53:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T07:53:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58863#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58863\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#8217;s First U.S.-Cleared Candidate Targets Immunocompromised Populations\",\"datePublished\":\"2026-03-05T07:53:39+00:00\",\"dateModified\":\"2026-03-05T07:53:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58863\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ab&amp;B Bio-Tech\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2627\",\"mRNA\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58863#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58863\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58863\",\"name\":\"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China's First U.S.-Cleared Candidate Targets Immunocompromised Populations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-05T07:53:39+00:00\",\"dateModified\":\"2026-03-05T07:53:40+00:00\",\"description\":\"Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China's first and the world's third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58863#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58863\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58863#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#8217;s First U.S.-Cleared Candidate Targets Immunocompromised Populations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China's First U.S.-Cleared Candidate Targets Immunocompromised Populations - Insight, China&#039;s Pharmaceutical Industry","description":"Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China's first and the world's third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58863","og_locale":"en_US","og_type":"article","og_title":"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China's First U.S.-Cleared Candidate Targets Immunocompromised Populations","og_description":"Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China's first and the world's third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.","og_url":"https:\/\/flcube.com\/?p=58863","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T07:53:39+00:00","article_modified_time":"2026-03-05T07:53:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58863#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58863"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#8217;s First U.S.-Cleared Candidate Targets Immunocompromised Populations","datePublished":"2026-03-05T07:53:39+00:00","dateModified":"2026-03-05T07:53:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58863"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ab&amp;B Bio-Tech","Clinical trial approval \/ initiation","HKG: 2627","mRNA","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58863#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58863","url":"https:\/\/flcube.com\/?p=58863","name":"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China's First U.S.-Cleared Candidate Targets Immunocompromised Populations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-05T07:53:39+00:00","dateModified":"2026-03-05T07:53:40+00:00","description":"Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its self-developed mRNA Mpox vaccine. The candidate becomes China's first and the world's third mRNA Mpox vaccine to receive U.S. regulatory clearance for clinical trials, positioning the company to address unmet needs in immunocompromised patient populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58863#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58863"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58863#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ab&amp;B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine \u2013 China&#8217;s First U.S.-Cleared Candidate Targets Immunocompromised Populations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58863"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58863\/revisions"}],"predecessor-version":[{"id":58866,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58863\/revisions\/58866"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}